TET2 and myeloproliferative neoplasm: To conclude, given the continued aging of the global population (with adults aged 65 and over estimated to constitute 16% of the global population by 2050 [20]), the high incidence of MPNs in the over-65 age group, the increasing incidence of DTA mutations with age [7,8,9,10,11] and the association of DTA mutations with both MPN and cardiovascular risk [12], the observation that DTA mutations (especially mutations in TET2) may be an independent risk factor for thrombosis in PV is particularly pertinent.